CAS: 2149-70-4; H-Arg(No2)-Oh

上下游产品

CAS号74-79-3 L-精氨酸 | CAS号1119-34-2 L-精氨酸盐酸盐 | CAS号2188-18-3 B°C-硝基-L-精氨酸 | CAS号157-06-2 D-精氨酸 | CAS号18635-55-7 甘氨酰-L-精氨酸 | CAS号74-79-3 L-精氨酸 | CAS号2896-20-0 H-Arg-Val-OH ac... | CAS号15706-88-4 ARG-ASP | CAS号16709-12-9 H-Ala-Arg-OH | CAS号2304-98-5 ZL-Arg(NO2)-羟基 | CAS号2188-18-3 B°C-硝基-L-精氨酸 | CAS号2047-13-4 H-ARG-PHE-OH | CAS号15706-89-5 H-ARG-GLU-OH | CAS号40968-46-5 H-ARG-LYS-OH

Alkaline Earth Salt Of/the/ Methylsulfuric Acid 反应生成N'-硝基-L-精氨酸
参考文献:Wechsler,Hoppe-Seyler´s Zeitschrift Für Physiologische Chemie,1912,Vol. 78,P. 54
标题:Wechsler,Hoppe-Seyler´s Zeitschrift Für Physiologische Chemie,1912,Vol. 78,P. 54

专利信息

专利号:WO-9312076-A1
优先权日:1991-12-13
标题:Reagents for automated synthesis of peptide analogs
发明人：WEBB THOMAS ROY
权利人:CORVAS INT INC
摘要:Reagents suitable for synthesis of peptide analogs using automated peptide synthesis and procedures for synthesis of peptide analogs are provided.

专利号:US-5283293-A
优先权日:1990-12-14
标 题:Reagents for automated synthesis of peptide analogs
发明人：WEBB THOMAS R
权利人:CORVAS INC
摘要:Reagents suitable for synthesis of peptide analogs using automated peptide synthesis and procedures for synthesis of peptide analogs are provided.

专利号:US-5367072-A
优先权日:1990-12-14
标 题 :Reagents for automated synthesis of peptide analogs
发明人：WEBB THOMAS R
权利人:CORVAS INT INC
摘要:Reagents suitable for synthesis of peptide analogs using automated peptide synthesis and procedures for synthesis of peptide analogs are provided.

专利号:US-4581168-A
优先权日:1983-02-21
标题:Synthesis of hpGRF (Somatocrinin) in liquid phase and intermediate peptides
发明人：DIAZ JOSEPH; DEMARNE HENRI; RONCUCCI ROMEO; SCHMELCK PAUL-HENRY
权利人:SANOFI SA
摘要:The invention relates to synthesis of hpGRF (Somatocrinin) in liquid phase and to intermediate peptides, comprising:--coupling, one after the other and in the order of the sequence of the GRF, the fragments in which: (a) the side acid functions of the aspartic and glutamic acids and the side amine function of the lysine are protected by protector groups stable in the conditions of deprotection of the group Boc, (b) the guanidine function of the arginine is protected by protonation, and (c) the N-terminal amino acid is protected on the amine by the Boc group;--selectively eliminating the group Boc from the N-terminal amine of the peptide in phase of elongation by hydrolysis with trifluoroacetic acid, said coupling being effected in an aprotic polar solvent and--eliminating, at the end of sequence, all the protector groups by hydrolysis with the aid of a 0.1 to 1M solution of methanesulfonic or trifluoromethanesulfonic acid in trifluoroacetic acid.

专利号:US-2002022022-A1
优先权日:2000-05-19
标题 :Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors
发明人：SHI YI; ZALEWSKI ANDREW
摘要:The present invention is directed to a method for the prophylactic and therapeutic treatment of diseases or disorders associated with the abnormal proliferation and extracellular matrix synthesis of smooth muscle cells (SMC) and fibroblasts due to activation of NAD(P)H and/or increased ROS generation. The method involves the administration of an NAD(P)H oxidase inhibitor(s) and/or antioxidant(s) to a mammal in an amount sufficient to treat the disease or disorder prophylactically or therapeutically. The NAD(P)H oxidase inhibitor inhibits the synthesis or translocation of NAD(P)H subunits, thereby blocking the generation of intracellular reactive oxygen species (ROS) and thus the proliferation and extracellular matrix synthesis of SMC and fibroblasts. Similarly, the administration of antioxidants blocks the generation of intracellular ROS, thereby inhibiting SMC and fibroblast proliferation and extracellular matrix synthesis. In addition to the prevention and treatment of vascular disease, such as atherosclerosis, graft disease, and restenosis, NAD(P)H oxidase inhibitors and antioxidants may be useful for the prevention and treatment of other conditions by decreasing cell proliferation and extracellular matrix synthesis associated therewith. These conditions include arthritis, keloid formation, cancer, tissue and organ fibrosis, and complications related to organ transplantation, metabolic syndrome, and radiation therapy.

专利号:US-4152322-A
优先权日:1978-04-28
标 题 :Process for selective reduction of nitroarginyl peptides with titanium (iii)
发明人：FREIDINGER ROGER M
权利人:MERCK & CO INC
摘要:Nitroarginyl peptides are selectively reduced to the corresponding arginyl peptides by titanium (III). The nitro protecting group which is labile toward nucleophilic reagents is retained through part of a synthesis and selectively removed prior to treatment with nucleophiles such as hydrazine and ammonia. The selectivity of titanium (III) for removal of the nitro functionality increases the flexibility of this protecting group in the synthesis of arginyl peptides. The present novel process is useful in the synthesis of medicinal peptides such as molluscan cardiac stimulant H-Phe-Met-Arg-Phe-NH 2 .